Company overview
SCIEX offers LC-MS/MS systems, including Triple Quad and QTRAP models, for high-sensitivity analyte quantification and separation in pharmaceutical R&D and regulatory compliance testing. Their nominal mass spectrometers provide superior selectivity over HPLC, enabling faster sample throughput and accurate compound classification. Additional solutions include software and high-resolution mass spectrometry for drug screening and clinical diagnostics.
SCIEX is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include sciex lc-ms, triple quad ms, qtrap systems, pharma mass spec, lc-ms/ms vendor.
Structured facts
- Website
- https://sciex.com/
- Markets served
- United States & Americas
- Keywords
- sciex lc-ms, triple quad ms, qtrap systems, pharma mass spec, lc-ms/ms vendor
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What LC-MS/MS capabilities does SCIEX provide for pharma R&D?
- SCIEX Triple Quad and QTRAP systems deliver high selectivity, sensitivity for MRM analysis, and QTRAP functionality for improved MS/MS confirmation and analyte separation from matrices.
- Are SCIEX systems compliant for regulated pharmaceutical testing?
- SCIEX LC-MS/MS systems support regulatory compliance with accurate quantification, qualifying components, and advantages over HPLC for reporting. Their clinical diagnostic portfolio is designated For In Vitro Diagnostic Use.
- What geographies does SCIEX serve for mass spectrometry solutions?
- SCIEX provides global mass spectrometry solutions including LC-MS, with products available internationally though not in all regions for certain clinical diagnostics.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
